<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421040</url>
  </required_header>
  <id_info>
    <org_study_id>17-006298</org_study_id>
    <nct_id>NCT04421040</nct_id>
  </id_info>
  <brief_title>Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors</brief_title>
  <official_title>Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are gathering information to see if using an FDA approved implantable device can
      help with monitoring of your heart arrhythmias.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>50 patients with TTR-wt cardiac amyloidosis will be monitored with an implantable loop recorder to determine frequency of atrial and ventricular arrhythmias. After 6 months the device will be explanted unless required for further clinical monitoring.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sudden death</measure>
    <time_frame>6 months</time_frame>
    <description>Total number of patients with sudden death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial arrhythmias</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of atrial arrhythmias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High grade AV block</measure>
    <time_frame>6 months</time_frame>
    <description>Total number of patients with high grade AV block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sinus node dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>Total number of patients with sinus node dysfunction</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>TTR Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of Biotronic 3 Device for a 6 month period. After the 6 month monitoring period, the patient will have the Biotronic 3 device removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biotronic 3 implant of device</intervention_name>
    <description>The Biotronic 3 device will be implanted by the research team physician.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biotonic 3 explant of device</intervention_name>
    <description>The Biotronic 3 device will be removed from the patient by the research team physician.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiac biopsy or technetium pyrophosphate scintigraphy confirmed patients

          -  Stage I, II, and early and late stage III in numbers as described , irrespective of EF
             or NYHA functional class

          -  Patients aged 18 -85, both genders and of all races and ethnicities.

          -  Patients must be competent to give informed consent.

          -  Patients must be able to have the Biomonitor 3 implanted.

        Exclusion Criteria:

          -  Significant coronary artery disease &gt; 75% luminal stenosis in at least 1 epicardial
             vessel (by cardiac catheterization or coronary computed tomography), or history of
             myocardial infarction or coronary revascularization.

          -  Congenital heart disease.

          -  Pregnant patients

          -  Patients whose heart failure is felt to be secondary to primary valvular disease
             (&gt;moderate/severe mitral regurgitation), uncorrected thyroid disease, obstructive or
             hypertrophic cardiomyopathy, pericardial disease or a systemic illness.

          -  Absolute contraindications to cardiac MRI (such as renal failure with GFR&lt;30%).

          -  Unwilling or unable to provide informed consent.

          -  Patients with other life threatening diseases that would likely decrease their life
             expectancy over the next four years.

          -  Patients who are post cardiac transplant.

          -  Difficulty to attend the follow-up schedule due to a history of medical noncompliance,
             difficulty, or unwillingness to return to the study center for follow up.

          -  Unwilling or able to have the Biomonitor 3 interrogated

          -  Patients who already have an ICD or PPM implanted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Grace Lin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

